These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26089490)

  • 21. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV vaccine development--improving on natural immunity.
    Johnston MI; Fauci AS
    N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
    [No Abstract]   [Full Text] [Related]  

  • 23. Virology. Moving forward in HIV vaccine development.
    Letvin NL
    Science; 2009 Nov; 326(5957):1196-8. PubMed ID: 19965456
    [No Abstract]   [Full Text] [Related]  

  • 24. Remodeling of dynamic structures of HIV-1 envelope proteins leads to synthetic antigen molecules inducing neutralizing antibodies.
    Nakahara T; Nomura W; Ohba K; Ohya A; Tanaka T; Hashimoto C; Narumi T; Murakami T; Yamamoto N; Tamamura H
    Bioconjug Chem; 2010 Apr; 21(4):709-14. PubMed ID: 20359196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
    Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
    Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virology. HIV may shed some protection as it jumps to new hosts.
    Cohen J
    Science; 2004 Mar; 303(5666):1956. PubMed ID: 15044774
    [No Abstract]   [Full Text] [Related]  

  • 27. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current world literature.
    Curr Opin HIV AIDS; 2009 Sep; 4(5):453-7. PubMed ID: 20046137
    [No Abstract]   [Full Text] [Related]  

  • 29. An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions.
    Ghunaim H; Kumar A; Torres J; Diaz-Mitoma F; Azizi A
    Vaccine; 2011 Aug; 29(35):5950-8. PubMed ID: 21718739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies to HIV-1: aiming at the right target.
    Eggink D; Melchers M; Sanders RW
    Trends Microbiol; 2007 Jul; 15(7):291-4. PubMed ID: 17566740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Few clues for AIDS vaccines from structural data on gp120 and its receptors and antibodies.
    Kohler H; Muller S; Schiffer M; Nara PL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):315-6. PubMed ID: 10077183
    [No Abstract]   [Full Text] [Related]  

  • 32. Receptor binding domain based HIV vaccines.
    Liu H; Bi W; Wang Q; Lu L; Jiang S
    Biomed Res Int; 2015; 2015():594109. PubMed ID: 25667925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B cell liaison confounds HIV-1 evolution.
    McHeyzer-Williams MG
    Cell; 2014 Jul; 158(3):475-6. PubMed ID: 25083862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV gp120 vaccine (Chiron).
    Drugs R D; 1999 Jun; 1(6):445-7. PubMed ID: 10566078
    [No Abstract]   [Full Text] [Related]  

  • 35. Update on HIV vaccines: which way now?
    Stevceva L
    Curr Med Chem; 2011; 18(26):3952. PubMed ID: 21824097
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV vaccine AIDSVAX.
    Drugs R D; 1999 Jun; 1(6):456-8. PubMed ID: 10566083
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of gp120 on dendritic cell-derived chemokines: relevance for the efficacy of gp120-based vaccines for HIV-1.
    Vani J; Sharma M; Shaila MS; Kaveri SV; Bayry J
    Clin Vaccine Immunol; 2012 Aug; 19(8):1335-6. PubMed ID: 22739696
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV vaccine vCP205. ALVAC-HIV vCP205, ALVAC vCP205.
    Drugs R D; 1999 Jun; 1(6):459-60. PubMed ID: 10566084
    [No Abstract]   [Full Text] [Related]  

  • 39. Infectious disease: Beating the big three.
    Bourzac K
    Nature; 2014 Mar; 507(7490):S4-7. PubMed ID: 24611168
    [No Abstract]   [Full Text] [Related]  

  • 40. HIV: Sequential vaccine elicits broadly neutralizing antibodies.
    Flemming A
    Nat Rev Drug Discov; 2016 Nov; 15(11):748-749. PubMed ID: 27807354
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.